Rare diseases research expanding collaborative translational research opportunities

Chest

Volumn 144, Issue 1, 2013, Pages 16-23

  Groft, Stephen C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; APROTININ; ATOVAQUONE; AZTREONAM; AZTREONAM LYSINE; BEDAQUILINE; BERACTANT; BOSENTAN; CALFACTANT; COTRIMOXAZOLE; CRIZOTINIB; FOLINIC ACID; ILOPROST; IVACAFTOR; NEW DRUG; NITRIC OXIDE; ORPHAN DRUG; PROSTACYCLIN; PROTEIN C; RECOMBINANT ANTITHROMBIN III; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIFAPENTINE; TADALAFIL; TOBRAMYCIN; TREPROSTINIL; TRIMETREXATE GLUCURONATE;

ANTITHROMBIN III DEFICIENCY; BUDGET; CYSTIC FIBROSIS; DISEASE REGISTRY; FULMINATING PURPURA; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NATIONAL HEALTH ORGANIZATION; NEGLECTED DISEASE; NEONATAL RESPIRATORY DISTRESS SYNDROME; PATIENT ADVOCACY; PERSISTENT PULMONARY HYPERTENSION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PSEUDOMONAS INFECTION; PUBLIC-PRIVATE PARTNERSHIP; PULMONARY HYPERTENSION; RARE DISEASE; RESEARCH PRIORITY; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; THROMBOSIS; TRANSLATIONAL RESEARCH; VEIN THROMBOSIS;

EID: 84880072331     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0606     Document Type: Note

References (22)

1. Collins F. An audience with...Francis Collins. Interviewed by Asher Mullard. Nat Rev Drug Discov. 2011; 10 (1): 14.
2. Pharmaceutical and Research Manufacturers Association. Drug discovery and development. Pharmaceutical Research and Manufacturers of America website. http://www.phrma.org/research/drug-discovery-development. Accessed February 18, 2013.
3. Health Promotion and Disease Prevention Amendments of 1984, Public Law 98-551, October 30, 1984.
4. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC): Rare Diseases and Orphan Drugs. National Institutes of Health website. http://report. nih.gov/categorical-spending.aspx. Accessed February 18, 2013.
5. Long G, Works J. Innovation in the biopharmaceutical pipeline: a multidimensional view. Pharmaceutical Research and Manufacturers of America website. http://phrma.org/sites/default/files/2435/ 2013innovationinthebiopharmaceutical pipeline-analysisgroupfinal.pdf. Accessed February 18, 2013.
6. Orphan Product Approvals and Designations Orphan Drug Product designation database. Food and Drug Administration website. http://www.accessdata.fda.gov/ scripts/opdlisting/oopd/index.cfm. Accessed February 18, 2013.
7. Orphan Drug Act, Public Law 97-414, January 4, 1983.
8. Collins FS. Reengineering translational science: the time is right. Sci Transl Med. 2011; 3 (90): 90cm17.
9. Harris PA, Scott KW, Lebo L, Hassan N, Lightner C, Pulley J. ResearchMatch: a national registry to recruit volunteers for clinical research. Acad Med. 2012; 87 (1): 66-73.
10. McKew JC, Pilon AM. NIH TRND program: successes in preclinical therapeutic development. Trends Pharmacol Sci. 2013; 34 (2): 87-89.
11. Bridging Interventional Development Gaps (BrIDGs) program. National Center for Advancing Translational Sciences website. http://www.ncats.nih.gov/ about/faq/bridgs/bridgs-faq. html. Accessed February 18, 2013.
12. Rare Diseases Act of 2002, Public Law 107-280, November 6, 2002.
13. Griggs RC, Batshaw M, Dunkle M, et al; Rare Diseases Clinical Research Network. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009; 96 (1): 20-26.
14. ORDR co-sponsored scientific conferences. National Institutes of Health Office of Rare Diseases Research website. http://rarediseases.info.nih.gov/ Scientific-Conferences.aspx. Accessed February 18, 2013.
15. Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet. 2011; 377 (9771): 1057-1059.
16. Rubinstein YR, Groft SC, Bartek R, et al. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemp Clin Trials. 2010; 31 (5): 394-404.
17. Rubinstein YR, Groft SC. Driving interest in consolidating resources for the creation of a global rare disease patient registry. Contemp Clin Trials. 2010; 31 (5): 393.
18. About the Registry of Patient Registries (ROPR). Agency for Health Research and Quality website. https://patientregistry. ahrq.gov/about/. Accessed February 18, 2013.
19. Common Data Elements Overview. National Institutes of Health Office of Rare Diseases Research website. http://www.grdr.info/index.php?option 5 com-content&view 5 article& id 5 3&Itemid 55. Accessed February 18, 2013.
20. Maximizing what we learn from clinical trials: National Institute of Neurological Disorders and Stroke Common Data Elements. National Institutes of Health National Institute of Neurological Disorders and Stroke website. http://www.ninds. nih.gov/about-ninds/message/message-CDE.htm. Accessed February 18, 2013.
21. Common Data Element Resource Portal. National Library of Medicine website. http://cde.nih.gov. Accessed February 18, 2013.
22. Workshop on Natural History Studies of Rare Diseases. Food and Drug Administration website. http://www.fda.gov/ForIndustry/ DevelopingProductsforRareDiseasesConditions/OOPDNewsArchive/ucm292294.htm. Accessed February 18, 2013.